Chronic hepatitis B virus (HBV) infection is a common cause of liver disease globally, with a
disproportionately high burden in South-East Asia. Vaccines and nucleoside or nucleotide …

Multiple new therapeutic approaches are currently being developed to achieve sustained,
off-treatment suppression of HBV, a persistent hepatotropic infection that kills~ 2,000 people …

SARS-CoV-2 has caused the global COVID-19 pandemic. Although passively delivered
neutralizing antibodies against SARS-CoV-2 show promise in clinical trials, their mechanism …

Chronic hepatitis B is caused by prolonged infection with the hepatitis B virus (HBV), which
can substantially increase the risk of developing liver disease. Despite the development of …

Many of the currently available COVID-19 vaccines and therapeutics are not effective
against newly emerged SARS-CoV-2 variants. Here, we developed the metallo-enzyme …

Glypican-3 (GPC3) is a well-characterized hepatocellular carcinoma (HCC)-associated
antigen, yet anti-GPC3 therapies have achieved only minimal clinical progress. CD47 is a …

Hepatitis B virus (HBV) affects approximately 250 million patients worldwide, resulting in the
progression to cirrhosis and hepatocellular carcinoma, which are serious public health …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged into the human
population in late 2019 and caused the global COVID-19 pandemic. SARS-CoV-2 has …

Hepatitis B virus infection affects over 250 million chronic carriers, causing more than
800,000 deaths annually, although a safe and effective vaccine is available. Currently used …

Background & Aims Production of neutralizing antibodies against hepatitis B surface antigen
(HBsAg) is dysregulated in patients with persistent hepatitis B virus (HBV) infection. We …